Beyond Cancer Cells: How the Tumor Microenvironment Drives Cancer Progression
Cells · 09.10.2024 · 13 (19) · 1666
DOI: 10.3390/cells13191666 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 09.10.2024. Verfasst von Hussein Sabit und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biotechnology, College of Biotechnology, Misr University for Science and Technology, Giza P.O. Box 77, Egypt. Hauptthemen laut MEDLINE: Tumor Microenvironment, Disease Progression. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 205 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Liver cancer represents a substantial global health challenge, contributing significantly to worldwide morbidity and mortality. It has long been understood that tumors are not composed solely of cancerous cells, but also include a variety of normal cells within their structure. These tumor-associated normal cells encompass vascular endothelial cells, fibroblasts, and various inflammatory cells, including neutrophils, monocytes, macrophages, mast cells, eosinophils, and lymphocytes. Additionally, tumor cells engage in complex interactions with stromal cells and elements of the extracellular matrix (ECM). Initially, the components of what is now known as the tumor microenvironment (TME) were thought to be passive bystanders in the processes of tumor proliferation and local invasion. However, recent research has significantly advanced our understanding of the TME’s active role in tumor growth and metastasis. Tumor progression is now known to be driven by an intricate imbalance of positive and negative regulatory signals, primarily influenced by specific growth factors produced by both inflammatory and neoplastic cells. This review article explores the latest developments and future directions in understanding how the TME modulates liver cancer, with the aim of informing the design of novel therapies that target critical components of the TME.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Biotechnology, College of Biotechnology, Misr University for Science and Technology, Giza P.O. Box 77, Egypt.
- Institute of Laboratory Medicine and Pathobiochemistry, Molecular Diagnostics, Hospital of the Universities of Giessen and Marburg (UKGM), Philipps University Marburg, Baldinger Str., 35043 Marburg, Germany.
- Institute of Laboratory Medicine and Pathobiochemistry, Molecular Diagnostics, Hospital of the Universities of Giessen and Marburg (UKGM), Justus Liebig University Giessen, Feulgenstr. 12, 35392 Giessen, Germany.
- Department of Environmental Biotechnology, College of Biotechnology, Misr University for Science and Technology, Giza P.O. Box 77, Egypt.
- Department of Surgery, College of Medicine, Misr University for Science and Technology, Giza P.O. Box 77, Egypt.
- Department of Surgery, College of Medicine, Cairo University, Giza 12613, Egypt.
ORCID-Profile: Hussein Sabit, Borros Arneth, Shaimaa Abdel-Ghany, Periasamy Selvaraj
Förderung
- NCI NIH HHS
Zitieren
APA
Sabit, H., Arneth, B., Abdel-Ghany, S., Madyan, E. F., Ghaleb, A. H., Selvaraj, P., Shin, D. M., Bommireddy, R., & Elhashash, A. (2024). Beyond Cancer Cells: How the Tumor Microenvironment Drives Cancer Progression. Cells, 13(19), 1666. https://doi.org/10.3390/cells13191666
Vancouver
Sabit H, Arneth B, Abdel-Ghany S, Madyan EF, Ghaleb AH, Selvaraj P, et al. Beyond Cancer Cells: How the Tumor Microenvironment Drives Cancer Progression. Cells. 2024;13(19):1666. doi:10.3390/cells13191666
BibTeX
@article{Sabit2024,
author = {Sabit, Hussein and Arneth, Borros and Abdel-Ghany, Shaimaa and Madyan, Engy F and Ghaleb, Ashraf H and Selvaraj, Periasamy and Shin, Dong M and Bommireddy, Ramireddy and Elhashash, Ahmed},
title = {Beyond Cancer Cells: How the Tumor Microenvironment Drives Cancer Progression},
journal = {Cells},
year = {2024},
volume = {13},
number = {19},
pages = {1666},
doi = {10.3390/cells13191666}
}
EUVIMED